Molecular subtyping, prognosis, and treatment of bladder cancer
US11208697B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jan 19, 2018 |
| Grant date | Dec 28, 2021 |
| Priority date | — |
| Expiry date | Jun 23, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/166
- WIPO fieldMedical technology
- WIPO sectorInstruments
Abstract
The present invention relates to methods, systems and kits for the diagnosis, prognosis, and treatment of bladder cancer in a subject. The invention also provides biomarkers that define subgroups of bladder cancer, clinically useful classifiers for distinguishing bladder cancer subtypes, bioinformatic methods for determining clinically useful classifiers, and methods of use of each of the foregoing. The methods, systems and kits can provide expression-based analysis of biomarkers for purposes of subtyping bladder cancer in a subject. Further disclosed herein, in certain instances, are probe sets for use in subtyping bladder cancer in a subject. Classifiers for subtyping a bladder cancer are provided. Methods of treating bladder cancer based on molecular subtyping are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.